Join our keynote, where we will unravel why excipients are making a stylish comeback in Pharma and explore their resurgence in modern medicine.
 

Speakers: 

• Nigel Langley, Gaylord Chemical Company, Global Technical Director Gaylord Chemical LLC ; IPEC- Americas Immediate Past Chair 
• Joseph Zeleznik, IPEC-Americas, Board Member & Chair

• Beyond Traditional Roles: Explore how excipients are no longer passive additives but active contributors to drug efficacy and delivery, offering diverse functionalities.

• Precision Medicine and Tailored Therapies: Delve into the role of excipient solutions in enabling precision medicine by allowing customized drug delivery profiles, optimized for individual patients.

• Enhancing Patient Adherence and Experience: Learn how excipient innovations are transforming patient experiences, from taste-masking to novel dosage forms, resulting in better medication compliance and outcomes.

Join us for us for a series of rapid-fire talks on technological innovations in excipients!
 

Explore novel applications in neurodegenerative diseases, gene therapy, and biotechnology, showcasing innovative structures, mechanisms, challenges, and results, with a focus on Alzheimer's, Parkinson's, rare genetic disorders, and potential expansion to longevity and infectious diseases, presenting a non-viral gene delivery platform and demonstrating CD utilization in vaccine adjuvants and biotechnological tools.

Speakers: 

• Dr Tamas Sohajda, CarboHyde, CEO

At Jurata we are focused on eliminating the need for cold chain storage of a vaccines and biologics, including mRNA-LNPs, in order to improve global health equity. Our novel stabalization technology is 10x more efficient to produce than lyophilized products and allows for sublingual and buccal delivery.

Speakers: 

• Denise Reaves, Jurata Thin Film, Senior Analytical Scientist

How to identify opportunities for novel excipients that solve formulation and process challenges; Needs of the industry for novel excipients, ways to identify current gaps and work together to resolve them, 1-2 key examples of common process challenges that might be solvable with novel excipients.

Speakers: 

• Dr. Björn-Hendrik Peters, Bristol Myers Squibb, Principal Scientist

Have burning questions about excipient functionalities, selection criteria, or their role in drug formulation? Join us as we bring together a seasoned excipient expert to address your queries, share insights, and offer a deeper understanding of these vital components. Whether you're a pharmaceutical professional, researcher, or simply curious about the science behind medicines.

The growing awareness of the environmental and health risks associated with (PFAS) has led to a global movement to phase out these chemicals from various products. In the pharmaceutical industry, PFAS have been used in some excipients due to their unique properties but concerns about potential health effects have prompted regulators and pharmaceutical companies to take action to reduce their use.
 

• Evaluating alternative excipients that can maintain product efficacy while reducing reliance on PFAS.
• What are the challenges in removing PFAS from products and the associated regulatory aspects
• Examine regulatory compliance and adaptations in response to PFAS concerns

In Pharma, excipients, often underappreciated despite their essential role in drug formulation and delivery, are gaining renewed attention. With growing investments in technology and increasing consumer demand for natural ingredients, excipients are taking on an expanded role. Join our esteemed panel of experts as they delve into the evolving landscape of excipients, their increasing importance in enhancing drug effectiveness and patient outcomes, and the shifting dynamics in this field.
 

• Why excipients are regarded as unsung heroes in the industry 
• Understand how natural excipients can be leveraged to improve the solubility and bioavailability 
• Analyzing the potential of excipients in personalized medicine, addressing formulation challenges, and improving patient compliance
  
  

Speakers: 

• Dr. Björn-Hendrik Peters, Bristol Myers Squibb, Principal Scientist